Amy Ward
Psychiatric/Mental Health · Lancaster, PANPI 1497303697
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 60.9% of it on its own, with 22 other manufacturers making up the rest. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 478 payments — averaging $34.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$10K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$880
- AbbVie$798
- Johnson & Johnson$724
- Neurocrine Biosciences, Inc.$630
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$7,35645%
- Travel & lodging$5663%
- Food & beverage$8,24851%
- Education$1531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 122 | $9,943 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,361 |
| Otsuka America Pharmaceutical, Inc. | 45 | $880 |
| AbbVie | 63 | $798 |
| Johnson & Johnson | 47 | $724 |
| Neurocrine Biosciences, Inc. | 48 | $630 |
| Alkermes, Inc. | 31 | $599 |
| Ironshore Pharmaceuticals Inc. | 10 | $300 |
| Vanda Pharmaceuticals Inc. | 8 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $199 |
| Axsome Therapeutics, Inc. | 2 | $149 |
| Lundbeck LLC | 6 | $121 |
| Corium, LLC | 4 | $85 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Noven Pharmaceuticals, Inc. | 1 | $28 |
| Almatica Pharma LLC | 1 | $27 |
| Adlon Therapeutics L.p. | 1 | $25 |
| Renalytix AI, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $22 |
| Neuronetics, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$8,111
- Auvelity$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- INGREZZA$105
- JORNAY PM$101
How this compares
$16,323 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $188,244 |
| Invega SustennaPaliperidone Palmitate | 25 | $90,060 |
| Abilify MaintenaAripiprazole | 21 | $56,112 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $53,566 |
| VraylarCariprazine Hcl | 23 | $31,466 |
| TrintellixVortioxetine Hydrobromide | 62 | $29,708 |
| RexultiBrexpiprazole | 14 | $20,649 |
| Aripiprazole | 129 | $18,599 |
| Clozapine | 142 | $11,021 |
| Paliperidone ErPaliperidone | 54 | $7,092 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 114 | $5,851 |
| Jornay PmMethylphenidate Hcl | 12 | $5,649 |
| Bupropion XlBupropion Hcl | 201 | $5,508 |
| Perphenazine | 88 | $4,904 |
| Divalproex Sodium ErDivalproex Sodium | 88 | $4,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $9,943 | $188,24415 claims |
| Johnson & JohnsonInvega Sustenna | $724 | $90,06025 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $880 | $76,76135 claims |
| Alkermes, Inc.Lybalvi | $599 | $53,56633 claims |
| AbbVieVraylar | $798 | $31,46623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $199 | $29,70862 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $300 | $5,64912 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $2,252138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Lancaster
- Brandon PankiewiczLancaster$9K
- Mikaila Lugo-SchlegelLancaster$9K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.